These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 32493725

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
    Hastings NB, Wang X, Song L, Butts BD, Grotz D, Hargreaves R, Fred Hess J, Hong KK, Huang CR, Hyde L, Laverty M, Lee J, Levitan D, Lu SX, Maguire M, Mahadomrongkul V, McEachern EJ, Ouyang X, Rosahl TW, Selnick H, Stanton M, Terracina G, Vocadlo DJ, Wang G, Duffy JL, Parker EM, Zhang L.
    Mol Neurodegener; 2017 May 18; 12(1):39. PubMed ID: 28521765
    [Abstract] [Full Text] [Related]

  • 3. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
    Graham DL, Gray AJ, Joyce JA, Yu D, O'Moore J, Carlson GA, Shearman MS, Dellovade TL, Hering H.
    Neuropharmacology; 2014 Apr 18; 79():307-13. PubMed ID: 24326295
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacological Inhibition of O-GlcNAcase Enhances Autophagy in Brain through an mTOR-Independent Pathway.
    Zhu Y, Shan X, Safarpour F, Erro Go N, Li N, Shan A, Huang MC, Deen M, Holicek V, Ashmus R, Madden Z, Gorski S, Silverman MA, Vocadlo DJ.
    ACS Chem Neurosci; 2018 Jun 20; 9(6):1366-1379. PubMed ID: 29460617
    [Abstract] [Full Text] [Related]

  • 6. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
    Bartolomé-Nebreda JM, Trabanco AA, Velter AI, Buijnsters P.
    Expert Opin Ther Pat; 2021 Dec 20; 31(12):1117-1154. PubMed ID: 34176417
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.
    Yu Y, Zhang L, Li X, Run X, Liang Z, Li Y, Liu Y, Lee MH, Grundke-Iqbal I, Iqbal K, Vocadlo DJ, Liu F, Gong CX.
    PLoS One; 2012 Dec 20; 7(4):e35277. PubMed ID: 22536363
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.
    Selnick HG, Hess JF, Tang C, Liu K, Schachter JB, Ballard JE, Marcus J, Klein DJ, Wang X, Pearson M, Savage MJ, Kaul R, Li TS, Vocadlo DJ, Zhou Y, Zhu Y, Mu C, Wang Y, Wei Z, Bai C, Duffy JL, McEachern EJ.
    J Med Chem; 2019 Nov 27; 62(22):10062-10097. PubMed ID: 31487175
    [Abstract] [Full Text] [Related]

  • 16. O-GlcNAcylation: A regulator of tau pathology and neurodegeneration.
    Gong CX, Liu F, Iqbal K.
    Alzheimers Dement; 2016 Oct 27; 12(10):1078-1089. PubMed ID: 27126545
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
    Helboe L, Egebjerg J, Barkholt P, Volbracht C.
    Brain Res; 2017 Jun 15; 1665():22-35. PubMed ID: 28411086
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.